The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1279
Ophthalmic Azithromycin (AzaSite)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved azithromycin 1% ophthalmic solution (AzaSite – Inspire) for treatment of bacterial conjunctivitis in patients > 1 year old. It is formulated, according to the manufacturer, in a controlled-release delivery system that keeps the drug in the eye for several hours.

OTHER OPHTHALMIC ANTIBACTERIALS — Ophthalmic formulations of antibacterial drugs achieve high concentrations in the eye and may be effective clinically even when the organisms are reported to be resistant in vitro. According to Medical Letter consultants, all ophthalmic antibacterials appear to be effective for most cases of this generally self-limited infection.

Sulfacetamide is widely used, but it can cause contact sensitivity reactions and rarely has caused Stevens-Johnson syndrome. Neomycin also causes sensitization and other local reactions in about 5-10% of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ophthalmic Azithromycin (AzaSite)
Article code: 1279b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian